ZEISS Medical Technology announced CE mark approval for CIRRUS PathFinder, an innovative clinical support tool featuring artificial intelligence (AI) integration to enable more confident decision-making and accelerate clinicians' workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 utilises proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed feature of a new CIRRUS software release, which also provides AI-enhanced OCTA image quality and multi-layer segmentation, thereby helping to improve a practice's workflow efficiency and patient care.

"At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience."

"ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder."